Molecular Quality Controls Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Molecular Quality Controls Market Trends and Insights

Rising Test-Volume in Molecular Diagnostics

Diagnostic laboratories processed unprecedented volumes during the COVID-19 public-health emergency, with the FDA authorizing 291 molecular assays, demonstrating the scalability of high-throughput platforms.^{[2]Source: U.S. Department of Health and Human Services, “Testing & Diagnostics,” hhs.gov} Post-pandemic, volume remains elevated as labs extend molecular testing to pharmacogenomics, antimicrobial resistance surveillance, and hereditary cancer panels. Each multiplex target adds validation layers, compelling laboratories to rely on robust third-party controls to avoid analytical drift. Digital QC dashboards integrated with laboratory information systems have trimmed manual verification steps by 62.5%, underscoring technology’s role in managing rising workloads.

Increasing Adoption of Third-Party QC for ISO 15189 Accreditation

ISO 15189:2022 raises the bar for risk management and for point-of-care integration, pushing laboratories toward externally sourced controls that demonstrate traceability and independence. The first U.S. accreditation under the new version signaled an early inflection toward global compliance momentum. Laboratories have three years to transition, anchoring sustained demand for molecular quality controls market products.

Growing Incidence of Cancer and Genetic Disorders

Cancer incidence rates continue rising globally, with molecular testing becoming essential for precision oncology treatment decisions. NGS oncology panels interrogate hundreds of genes, copy-number events, and fusions, each demanding stringent controls for variant detection accuracy. Liquid-biopsy assays amplify complexity by requiring ultra-low-frequency variant detection, escalating the need for high-sensitivity synthetic controls. Similarly, hereditary disease panels covering 100 plus actionable genes require variant-specific controls to support correct clinical reporting.

Stricter External-Quality Assessment Mandates

The 2024 CLIA update introduced 23 new molecular proficiency tests and narrowed allowable error margins by 33.3%, compelling U.S. laboratories to upgrade QC procedures. The longitudinal analysis of 20 years of EQA schemes for PCR/NAAT-based bacterial detection reveals declining in-house assay usage and increased adoption of commercial quality controls. Parallel schemes in Europe under IVDR and ISO 15189 require regular proficiency participation, cementing a compliance-driven spending channel within the molecular quality controls market.

High Per-Run Cost of Molecular QC Materials

The economics of molecular quality controls present significant challenges for laboratories operating under constrained budgets, particularly as test complexity increases. NGS assays cut the overall cost of patient care compared with sequential PCR yet still demand expensive multi-analyte controls that can account for 4–7% of per-sample cost, a margin non-trivial to small laboratories. Fixed control costs scale poorly when test volumes are modest, prompting labs to stretch replacement intervals and potentially compromise analytical robustness. 

Complex Multi-Agency Regulatory Pathway

The regulatory landscape for molecular quality controls involves multiple agencies with overlapping jurisdictions, creating compliance complexity that extends product development timelines and increases costs. The FDA’s four-year phase-in of the LDT Final Rule requires device-like quality systems, medical-device reporting, and in many cases premarket review.^{[3]Source: U.S. Food and Drug Administration, “Medical Devices; Laboratory Developed Tests,” fda.gov} Parallel IVDR conformity assessments in Europe oblige manufacturers to address multiple audit bodies, lengthening product launches and raising compliance costs, especially for small suppliers. 

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product Type: Independent Controls Drive Market Leadership

Independent controls dominated with a 57.52% molecular quality controls market share in 2025, reflecting laboratories’ preference for vendor-neutral verification tools that satisfy ISO 15189 documentation requirements and mitigate platform bias. Bio-Rad’s Unity Data Management network, active in 38,000 labs, illustrates how third-party controls aggregate peer comparisons to detect systemic deviations quickly. Independent products span multi-analyte panels for respiratory pathogens to custom oncology variants, allowing labs to standardize across diverse instruments.  

Instrument-specific controls, though smaller, are projected to post a 7.12% CAGR through 2031 as automation and integrated sample-to-answer platforms expand. Manufacturer-tuned stability and lot-to-lot consistency save validation time, a decisive advantage in high-throughput environments. Yet vendor-lock fears linger, keeping independent controls the reference option for proficiency schemes. The molecular quality controls market therefore gravitates toward a dual-sourcing model in which labs deploy independent controls for accreditation while relying on instrument-specific materials for daily workflow continuity.

By Technology: PCR Dominance Faces NGS Disruption

PCR-based products retained 69.05% revenue in 2025, anchored by high-volume infectious disease testing where turnaround time and cost trump breadth. These controls typically contain stabilized viral or bacterial nucleic acids encapsulated in non-infectious particles for biosafety.  

NGS-based controls, however, are advancing at a 6.89% CAGR, reflecting oncology’s shift toward multi-gene panels and the rising use of comprehensive genomic profiling in hereditary disorders. Sample-preparation QC kits assess library complexity, fragment size, and adapter ligation efficiency before sequencing, reducing costly reruns. The molecular quality controls market size for NGS panels is poised to expand as reimbursement improves and sequencing costs continue to decline. Isothermal amplification controls occupy niche use cases such as point-of-care STI testing, where rapid qualitative answers suffice.

By Application: Infectious Diseases Leadership Under Oncology Pressure

Infectious-disease testing held 54.78% of the molecular quality controls market size in 2025, supported by continuous respiratory virus surveillance and mandated EQA participation for notifiable pathogens. Multi-target panels covering influenza, RSV, and SARS-CoV-2 remain baseline requirements for clinical labs.  

Oncology, forecast to grow at an 7.56% CAGR, is narrowing the gap. Liquid-biopsy innovation and adaptive cancer trials necessitate quantitative controls capable of detecting variants at allele frequencies below 0.5%. Laboratories also bundle QC data into electronic submission packages for U.S. FDA companion-diagnostic approvals, a procedural reality lifting control volumes per assay. Genetic and hereditary disease testing gains momentum through expanded carrier screens and pharmacogenomic guidance, propelling broader adoption of multiplex controls with calibrated variant distributions.

By End-User: IVD Manufacturers Accelerate Enterprise Integration

Clinical laboratories commanded 45.86% revenue in 2025, yet purchasing dynamics increasingly shift upstream. IVD manufacturers and CROs, growing at 7.31% CAGR, bundle controls into assay development pipelines to streamline FDA or CE marking dossiers. Control consumption spikes during validation, bridging analytical sensitivity, specificity, and limit-of-detection studies.  

Enterprise consolidation also moves QC selection to central corporate teams, prioritizing platforms offering data-integration APIs and automated lot-tracking. For hospital networks, middleware linking QC metrics with inventory data curtails wastage, giving suppliers that provide cloud dashboards a competitive edge. Academic medical centers remain important adopters, particularly where translational research creates novel assay designs demanding bespoke QC materials.

Geography Analysis

North America led with 37.82% revenue in 2025, buoyed by strong reimbursement, high test volume, and the FDA’s framework that elevates third-party controls from best practice to regulatory necessity. CLIA’s stricter performance thresholds compound demand as laboratories widen QC frequency to retain accreditation. Canada’s modernization of medical-device regulations supports accelerated pathways for innovative quality controls, sustaining steady regional growth.

Asia-Pacific is the fastest-growing geography with an 7.74% CAGR, propelled by government genomics programs and expanding private diagnostic chains. Japan’s reimbursement of NGS oncology panels and South Korea’s investment in cell-and-gene therapy manufacturing both translate to higher QC consumption for NGS workflows. China’s domestic instrument makers increasingly embed QC lot-tracking software, amplifying local demand. Despite fragmented regulations, the molecular quality controls market benefits from APAC’s push to harmonize quality standards with ISO 15189 and IVDR principles, fostering cross-border product adoption.

Europe exhibits consistent mid-single-digit growth as IVDR implementation compels laboratories and manufacturers to upgrade quality documentation. The United Kingdom’s National Health Service awards central laboratory contracts that require ISO 15189:2022 compliance, embedding QC use in procurement templates. Middle East & Africa and South America remain nascent but show double-digit incremental gains where new reference laboratories open. In these regions, infectious-disease surveillance projects funded by multilateral agencies often stipulate third-party controls, giving suppliers an early foothold.

Regulatory Landscape

Regulation affecting molecular quality controls is tightening alongside expanded oversight of molecular diagnostics. In the United States, CLIA requirements for control procedures for molecular tests (including use of multiple control materials and inhibition checks where applicable) establish baseline expectations for routine QC. FDA guidance for infectious-disease NGS diagnostics further reinforces the need for positive, negative, and internal controls to monitor process performance. FDA quality system expectations also rise as the Quality Management System Regulation (QMSR) takes effect in February 2026, increasing the emphasis on harmonized quality-system documentation and postmarket controls across IVD-related suppliers.

In Europe, EU Regulation 2017/746 (IVDR) shapes how control materials are handled within the conformity assessment ecosystem, including risk-based classification that links certain control materials to the risk class of the associated IVD. Companion diagnostics under IVDR add consultation steps with the EMA or national competent authorities, raising the level of documentation rigor around analytical performance and suitability claims. Transitional timelines under IVDR (including a May 26, 2026 milestone for certain Class C devices) and the global transition toward ISO 15189:2022 accreditation together reinforce demand for traceable, independently sourced molecular QC materials that support risk management across the testing lifecycle.

Market Opportunities and Future Outlook

A core opportunity lies in translating compliance requirements into scalable QC formats for multiplex, syndromic, and NGS workflows, where control burdens increase as assay complexity rises. CLIA control-procedure obligations for molecular tests and the limited applicability of IQCP for more complex molecular assays create whitespace for suppliers offering full-process controls (including inhibition-sensitive materials) and machine-readable documentation aligned to laboratory quality systems. As laboratories formalize ISO 15189:2022 risk management and traceability practices, control providers that pair third-party materials with data-management capabilities can differentiate by easing audit readiness and supporting cross-instrument comparability across consolidated lab networks.

Decentralization and automation also create whitespace for control designs that operate reliably outside traditional cold-chain, high-infrastructure settings. Development work around lyophilized and other stabilized control materials (including plasma-based controls designed for broader temperature stability) supports the need for QC suited to point-of-care and distributed testing models, while still meeting centralized quality expectations. Materials innovation, such as pseudovirus-based reference materials for nucleic acid testing, aligns with automated sample-to-answer systems, where controls that mimic clinical specimens and remain stable through extraction and amplification steps can support uptake across infectious disease, oncology, and emerging applications like cell and gene therapy quality control.